Sequella Partnerships

• National Institutes of Health (NIH) is the focal point of biomedical research in the United States, and conducts research in its own laboratories; supports the research of non-Federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad; helps in the training of research investigators; and fosters communication of medical information. Since 2001, the NIH has supported Sequella in a variety of collaboration structures, including study grants to fund development of diagnostic products, scientific support for R&D of diamine TB compounds, analytical characterization of drug candidates, and in vivo toxicity and pharmacology testing of lead therapeutic compounds. In 2006, Sequella obtained an exclusive worldwide license from the NIH to develop SQ109, an IND-stage new chemical entity targeted for the treatment of tuberculosis (TB).

• Laboratory Corporation of America (LabCorp) provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp licensed Sequella's B-SMART™ technologyto develop a new laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis and to commercially use the assay in the United States.

• European Developing Country Clinical Trials Partnership (EDCTP) and the Pan African Consortium for the Evaluation of Anti-TB Antibiotics (PanACEA) are respectively funding and coordinating Phase 2 clinical trials of SQ109, Sequella's lead anti-TB drug candidate.

• Daiichi-Sankyo Co., Ltd. of Tokyo, is one of Japan's largest pharmaceutical companies, and has a long history of discovering new classes of drugs, including the statin class of lipid-lowering drugs. Sequella entered into an exclusive license agreement for Sankyo's novel anti-tuberculosis translocase inhibitors. These inhibitors represent a potential new class of anti-tuberculosis agents that act through specific inhibition of mycobacterial translocase I, an enzyme required for cell wall synthesis. Under the agreement, Sankyo granted Sequella an exclusive world-wide license to make, market and sell these compounds for all indications.